Treating and Preventing HIV with Generic Drugs - Barriers in the United States

N Engl J Med. 2018 Jan 25;378(4):316-319. doi: 10.1056/NEJMp1710914.

Authors

Erika G Martin¹, Bruce R Schackman¹

Affiliation

¹ From the Rockefeller Institute of Government and the Department of Public Administration and Policy, University at Albany, State University of New York, Albany (E.G.M.); and the Department of Healthcare Policy and Administration, Weill Cornell Medical College, New York (B.R.S.).

PMID: 29365306
DOI: 10.1056/NEJMp1710914

No abstract available

MeSH terms

Anti-Retroviral Agents / economics
Anti-Retroviral Agents / therapeutic use*
Cost Savings
Drug Combinations
Drug Costs*
Drug Therapy, Combination
Drugs, Generic / economics
Drugs, Generic / therapeutic use*
HIV Infections / drug therapy*
HIV Infections / prevention & control
Humans
Insurance, Pharmaceutical Services / economics
Legislation, Drug
Marketing
United States

Substances

Anti-Retroviral Agents
Drug Combinations
Drugs, Generic